Dr. Hönle AG revised earnings guidance for the year 2021/2022. The Management Board therefore expects sales of EUR 125 million to EUR 130 million and an operating loss (LBIT) of EUR 3 million to EUR 4 million for the Hönle Group in the 2021/2022 financial year. To date, the Executive Board has been expecting sales of between EUR 125 million and EUR 130 million (PY: EUR 115 million) and an operating result (EBIT) of between EUR 9 million and EUR 11 million (PY: EUR 0.3 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.5 EUR | -0.76% | -2.99% | +11.43% |
05-08 | Dr. Hönle AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
02-26 | Dr. Hönle AG Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.43% | 127M | |
+16.68% | 87.2B | |
+21.80% | 72.13B | |
+18.00% | 36.82B | |
+25.04% | 34.67B | |
+12.66% | 28.34B | |
+4.41% | 27.06B | |
+6.88% | 26.98B | |
+20.37% | 26.3B | |
+20.64% | 25.5B |
- Stock Market
- Equities
- HNL Stock
- News Dr. Hönle AG
- Dr. Hönle AG Revises Earnings Guidance for the Year 2021/2022